

6. Quellen

1. Haddow A. Epidemiological evidence suggesting an infective element in the aetiology. In: Burkitt DP WD, ed. *Burkitt's Lymphoma*. Edinburgh: E&S Livingstone; 1970:198-209.
2. Epstein MA, Achong BD, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's Lymphoma. *Lancet*. 1964;1:702-703.
3. Dorfmann RF. Childhood lymphosarcoma in St. Louis, Missouri, clinically and histologically resembling Burkitt's lymphoma. *Cancer*. 1965;18:418.
4. Wright DH. Burkitt's tumour in England. A comparison with childhood lymphosarcoma. *Int J Cancer*. 1966;1:503-14.
5. Chan JK, Tsang WY, Ng CS, Wong CS, Lo ES. A study of the association of Epstein-Barr virus with Burkitt's lymphoma occurring in a Chinese population. *Histopathology*. 1995;26:239-45.
6. Gutierrez MI, Bhatia K, Barriga F, Diez B, Muriel FS, de Andreas ML, Epelman S, Risueno C, Magrath IT. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. *Blood*. 1992;79:3261-6.
7. Henle G, Henle W, Diehl V. Relation of Burkitt's tumor-associated herpes- γ -type virus to infectious mononucleosis. *Proc Natl Acad Sci U S A*. 1968;59:94-101.
8. Greenspan JS, Greenspan D, Lennette ET, Abrams DI, Conant MA, Petersen V, Freese UK. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. *N Engl J Med*. 1985;313:1564-71.
9. Ziegler JL, Drew WL, Miner RC, Mintz L, Rosenbaum E, Gershow J, Lennette ET, Greenspan J, Shillitoe E, Beckstead J, Casavant C, Yamamoto K. Outbreak of Burkitt's-like lymphoma in homosexual men. *Lancet*. 1982;2:631-3.
10. de-The G, Day NE, Geser A, Lavoue MF, Ho JH, Simons MJ, Sohler R, Tukei P, Vonka V, Zavadova H. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review. *IARC Sci Publ*. 1975:3-16.
11. Wolf H, Bogedain C, Schwarzmann F. Epstein-Barr virus and its interaction with the host. *Intervirology*. 1993;35:26-39.
12. Evans AS. The spectrum of infections with Epstein-Barr virus: a hypothesis. *J Infect Dis*. 1971;124:330-7.
13. Kafuko GW, Henderson BE, Kirya BG, Munube GM, Tukei PM, Day NE, Henle G, Henle W, Morrow RH, Pike MC, Smith PG, Williams EH. Epstein-Barr virus antibody levels in children from the West Nile District of Uganda. Report of a field study. *Lancet*. 1972;1:706-9.
14. Sumaya CV, Henle W, Henle G, Smith MH, LeBlanc D. Seroepidemiologic study of Epstein-Barr virus infections in a rural community. *J Infect Dis*. 1975;131:403-8.

15. Rickinson AB, Kieff E. Epstein-Barr-Virus. In: Fields BN, Knipe DM, Howly PM, Chanock RM, Melnick JL, Monath TP, Roizmann B, Straus SE, eds. *Fields Virology*. Philadelphia PA: Lippincott-Raven; 1996:2343-96.
16. Niedermann J, Evans A. Epstein-Barr-Virus. In: Evans AS, Kaslow RA, eds. *Viral infection of Humans*. New York: Plenum; 1997:253-83.
17. Sawyer RN, Evans AS, Niederman JC, McCollum RW. Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis. *J Infect Dis*. 1971;123:263-70.
18. Cohen JI. Epstein-Barr virus infection. *N Engl J Med*. 2000;343:481-92.
19. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. *Nature*. 1970;228:1056-8.
20. Nonoyama M, Huang CH, Pagano JS, Klein G, Singh S. DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. *Proc Natl Acad Sci U S A*. 1973;70:3265-8.
21. Prevot S, Hamilton-Dutoit S, Audouin J, Walter P, Pallesen G, Diebold J. Analysis of African Burkitt's and high-grade B cell non-Burkitt's lymphoma for Epstein-Barr virus genomes using in situ hybridization. *Br J Haematol*. 1992;80:27-32.
22. de-The G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. *Nature*. 1978;274:756-61.
23. Mueller NE, Evans AS, London WTJ. Viruses. In: Schottenfeld D, Fraumeni JF, Jr., eds. *Cancer Epidemiology and Prevention*. New York: Oxford University Press; 1996:502-31.
24. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. *Lancet*. 1991;337:805-9.
25. Hamilton-Dutoit SJ, Raphael M, Audouin J, Diebold J, Lisse I, Pedersen C, Oksenhendler E, Marelle L, Pallesen G. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. *Blood*. 1993;82:619-24.
26. Inghirami G, Grignani F, Sternas L, Lombardi L, Knowles DM, Dalla-Favera R. Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells. *Science*. 1990;250:682-6.
27. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. *N*

28. Mueller N. Epidemiologic studies assessing the role of the Epstein-Barr virus in Hodgkin's disease. *Yale J Biol Med.* 1987;60:321-32.
29. Hamilton-Dutoit SJ, Pallesen G. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. *Am J Pathol.* 1992;140:1315-25.
30. Hummel M, Anagnostopoulos I, Korbjuhn P, Stein H. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. *J Pathol.* 1995;175:263-71.
31. d'Amore F, Johansen P, Houmand A, Weisenburger DD, Mortensen LS. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO. *Blood.* 1996;87:1045-55.
32. Knowles DM. Biologic aspects of AIDS-associated non-Hodgkin's lymphoma. *Curr Opin Oncol.* 1993;5:845-51.
33. Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht C, Marelle L, van Krieken HJ, Pallesen G. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. *Am J Pathol.* 1993;143:1072-85.
34. Craig FE, Gulley ML, Banks PM. Posttransplantation lymphoproliferative disorders. *Am J Clin Pathol.* 1993;99:265-76.
35. Lager DJ, Burgart LJ, Slagel DD. Epstein-Barr virus detection in sequential biopsies from patients with a posttransplant lymphoproliferative disorder. *Mod Pathol.* 1993;6:42-7.
36. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. *Int J Cancer.* 1982;29:139-41.
37. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. *Am J Pathol.* 1995;146:1355-67.
38. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. *N Engl J Med.* 1995;333:693-8.
39. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. *IARC Sci Publ.* 1992:45-173.
40. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. *Am J Pathol.* 1992;140:769-74.

41. Qiu K, Tomita Y, Hashimoto M, Ohsawa M, Kawano K, Wu DM, Aozasa K. Epstein-Barr virus in gastric carcinoma in Suzhou, China and Osaka, Japan: association with clinico-pathologic factors and HLA-subtype. *Int J Cancer.* 1997;71:155-8.
42. Harn HJ, Chang JY, Wang MW, Ho LI, Lee HS, Chiang JH, Lee WH. Epstein-Barr virus-associated gastric adenocarcinoma in Taiwan. *Hum Pathol.* 1995;26:267-71.
43. Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. *J Virol.* 1987;61:1310-7.
44. Proceedings of the IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon, France, 17-24 June 1997. *IARC Monogr Eval Carcinog Risks Hum.* 1997;70:1-492.
45. Fingerroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. *Proc Natl Acad Sci U S A.* 1984;81:4510-4.
46. Menezes J, Jondal M, Leibold W, Dorval G. Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation. *Infect Immun.* 1976;13:303-10.
47. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. *Annu Rev Immunol.* 1997;15:405-31.
48. Kieff E. Epstein-Barr-Virus and its replication. In: Fields BN, Knipe DM, Howly PM, Chanock RM, Melnick JL, Monath TP, Roizmann B, Straus SE, eds. *Fields virology.* Philadelphia PA: Lippincott-Raven; 1996:2343-96.
49. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. *Cell.* 1985;43:831-40.
50. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. *Cell.* 1991;65:1107-15.
51. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. *Cell.* 1995;80:389-99.
52. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. *N Engl J Med.* 1998;338:1413-21.
53. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB, Kieff E. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. *Immunity.* 1995;2:155-66.

54. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. *Proc Natl Acad Sci U S A*. 1984;81:3806-10.
55. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. *J Virol*. 1995;69:253-62.
56. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. *J Virol*. 1990;64:2309-18.
57. Yokoyama A, Tanaka M, Matsuda G, Kato K, Kanamori M, Kawasaki H, Hirano H, Kitabayashi I, Ohki M, Hirai K, Kawaguchi Y. Identification of major phosphorylation sites of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP): ability of EBNA-LP to induce latent membrane protein 1 cooperatively with EBNA-2 is regulated by phosphorylation. *J Virol*. 2001;75:5119-28.
58. Ruf IK, Rhyne PW, Yang C, Cleveland JL, Sample JT. Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. *J Virol*. 2000;74:10223-8.
59. Hummel M, Anagnostopoulos I, Dallenbach F, Korbjuhn P, Dimmler C, Stein H. EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products. *Br J Haematol*. 1992;82:689-94.
60. Niedobitek G, Herbst H, Pitteroff S, Hansmann M, Dienemann D, Hartmann CA, Finn T, Stein H. [Demonstration of DNA tumor viruses in carcinomas of the upper respiratory tract]. *Verh Dtsch Ges Pathol*. 1990;74:390-3.
61. Magrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. *Am J Pediatr Hematol Oncol*. 1991;13:222-46.
62. Sinclair AJ, Fenton M, Delikat S. Interactions between Epstein-Barr virus and the cell cycle control machinery. *Histol Histopathol*. 1998;13:461-7.
63. Levy R, Warnke R, Dorfman RF, Haimovich J. The monoclonality of human B-cell lymphomas. *J Exp Med*. 1977;145:1014-28.
64. Yuen ST, Chung LP, Leung SY, Luk IS, Chan SY, Ho J. In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. *Am J Surg Pathol*. 1994;18:1158-63.
65. Chapel F, Fabiani B, Davi F, Raphael M, Tepper M, Champault G, Guettier C. Epstein-Barr virus and gastric carcinoma in Western patients: comparison of pathological parameters and p53 expression in EBV-positive and negative tumours. *Histopathology*. 2000;36:252-61.

66. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. *Cancer Res.* 2000;60:2745-8.
67. Yao Y, Minter HA, Chen X, Reynolds GM, Bromley M, Arrand JR. Heterogeneity of HLA and EBER expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. *Int J Cancer.* 2000;88:949-55.
68. Herbst H, Steinbrecher E, Niedobitek G, Young LS, Brooks L, Muller-Lantzsch N, Stein H. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. *Blood.* 1992;80:484-91.
69. Shibata D. Extraction of DNA from paraffin-embedded tissue for analysis by polymerase chain reaction: new tricks from an old friend. *Hum Pathol.* 1994;25:561-3.
70. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, Lenoir GM. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. *Proc Natl Acad Sci U S A.* 1987;84:8060-4.
71. Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. *J Virol.* 1998;72:9150-6.
72. Lacy J, Summers WP, Watson M, Glazer PM, Summers WC. Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line. *Proc Natl Acad Sci U S A.* 1987;84:5838-42.
73. Roncella S, Di Celle PF, Cutrona G, Carbone A, Sessarego M, Landonio G, Foa R, Rowe M, Ferrarini M. Cytogenetic rearrangement of C-MYC oncogene occurs prior to infection with Epstein-Barr virus in the monoclonal malignant B cells from an AIDS patient. *Leuk Lymphoma.* 1993;9:157-64.
74. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. *J Virol.* 1994;68:6069-73.
75. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS, Li YP. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. *Proc Natl Acad Sci U S A.* 1989;86:9524-8.
76. Delecluse HJ, Marafioti T, Hummel M, Dallenbach F, Anagnostopoulos I, Stein H. Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease. *J Pathol.* 1997;182:475-9.
77. Takada K, Ji Z, Fujiwara S, Shimizu N, Tanabe-Tochikura A. Partial elimination of Epstein-Barr virus plasmids from Burkitt's lymphoma cells by transfecting the BZLF1 gene. *J Virol.* 1992;66:5590-3.

78. Greifenegger N, Jager M, Kunz-Schughart LA, Wolf H, Schwarzmann F. Epstein-Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication. *J Virol.* 1998;72:9323-8.